ARQT vs. BBIO, LEGN, ELAN, CYTK, NUVL, GRFS, VKTX, TGTX, AXSM, and KRYS
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Arcutis Biotherapeutics vs.
Arcutis Biotherapeutics (NASDAQ:ARQT) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.
BridgeBio Pharma received 106 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 71.19% of users gave BridgeBio Pharma an outperform vote while only 65.26% of users gave Arcutis Biotherapeutics an outperform vote.
99.8% of BridgeBio Pharma shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Arcutis Biotherapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Arcutis Biotherapeutics has a net margin of -140.97% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.
In the previous week, BridgeBio Pharma had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 21 mentions for BridgeBio Pharma and 16 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.52 beat BridgeBio Pharma's score of 0.45 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.
Arcutis Biotherapeutics currently has a consensus price target of $16.60, suggesting a potential upside of 30.91%. BridgeBio Pharma has a consensus price target of $48.08, suggesting a potential upside of 42.28%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Arcutis Biotherapeutics.
Arcutis Biotherapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
BridgeBio Pharma beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARQT) was last updated on 1/17/2025 by MarketBeat.com Staff
Free ARQT Stock Alerts